이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Nurix Therapeutics 배당금

배당금 기준 확인 0/6

Nurix Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.9%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$2.25
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 NRIX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: NRIX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Nurix Therapeutics 시장 대비 배당 수익률

NRIX 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (NRIX)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.9%
3년 후 애널리스트 예측 (NRIX)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NRIX 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NRIX 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NRIX 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: NRIX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Nurix Therapeutics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics, Inc. Appoints Paula G. O’Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial

Price target decreased by 9.4% to US$24.09

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Chief Financial Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc. Announces Publication in the Journal Science Identifying A New Class of Btk Mutations That Are Susceptible to Nx-2127, A Novel Btk and Ikzf1/3 Degrader

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Chief Financial Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Presents Positive Clinical Data from its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, Nx-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics, Inc. Announces Partial Clinical Hold for Nx-2127 Phase 1 Trial

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Plans to Initiate Two New Phase 1b Dose Expansion Cohorts in Ongoing Phase 1a/1b Clinical Trial of NX-2127 in Patients with Relapsed or Refractory B-Cell Malignancies

Consensus revenue estimates increase by 39%

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 23%, EPS upgraded

Price target decreased by 7.7% to US$31.45

Full year 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Price target decreased to US$34.91

Nurix Announces Initial Nx-1607 Phase 1 Data Presented At the 37Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc) Demonstrating Targeted Cbl-B Inhibition in Patients with Advanced Malignancies

Nurix Therapeutics Inc. Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation Summit

Price target decreased to US$34.91

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Nurix Therapeutics, Inc. Appoints Edward C. Saltzman to its Board of Directors

Nurix Therapeutics, Inc. Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Price target decreased to US$38.20

Price target decreased to US$38.80

Nurix Therapeutics, Inc. has announced a Derivatives Offering in the amount of $54.996046 million.

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Nurix Therapeutics, Inc. Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Nurix Therapeutics, Inc.(NasdaqGM:NRIX) dropped from Russell 2000 Growth Index

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs At the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Chief Financial Officer exercised options to buy US$621k worth of stock.

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

Nurix Therapeutics, Inc. Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948

High number of new directors

Nurix Therapeutics, Inc. Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

Nurix Therapeutics Receives Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

Nurix Therapeutics, Inc. Announces Resignation of Jeffrey K. Tong as Class II Member of the Board and as a Member of the Board's Audit Committee and Compensation Committee

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Price target decreased to US$47.33

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

Chief Scientific Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of Nx-5948

Nurix: Advancing Targeted Protein Modulation Therapies